These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 4806018)

  • 1. In vitro and in vivo immunological effects of polyspecific F(ab')2 fragments in dogs.
    Wren SF; Koppenheffer TL; Martins AC; Shaipanich T; von Haefen U; Busch GJ; Wilson RE
    Surg Forum; 1973; 24():336-8. PubMed ID: 4806018
    [No Abstract]   [Full Text] [Related]  

  • 2. Survival of canine renal allografts after treatment with polyspecific F(ab')2 fragments.
    Abouna GM; Garver FA; Kogure H; DeLong TG; Andres GA
    Surg Forum; 1973; 24():318-20. PubMed ID: 4618655
    [No Abstract]   [Full Text] [Related]  

  • 3. Evaluation of organ specificity in renal allograft enhancement with F(ab') 2 fragments.
    Shaipanich T; Wren S; von Haefen U; Koppenheffer T; Busch G; Wilson RE
    Transplant Proc; 1973 Mar; 5(1):581-3. PubMed ID: 4572116
    [No Abstract]   [Full Text] [Related]  

  • 4. Passive enhancement of canine renal allografts with polyspecific F(ab')2 fragments.
    Wren SF; Martins AC; Von Haefen U; Busch GJ; Katske GE; Koppenheffer TL; Shaipanich T; Wilson RE
    Surgery; 1974 Jul; 76(1):112-20. PubMed ID: 4135410
    [No Abstract]   [Full Text] [Related]  

  • 5. Active or passive enhancement and allograft survival.
    Wilson RE
    Transplant Proc; 1972 Dec; 4(4):513-5. PubMed ID: 4405144
    [No Abstract]   [Full Text] [Related]  

  • 6. Passive immunotherapy for influenza A H5N1 virus infection with equine hyperimmune globulin F(ab')2 in mice.
    Lu J; Guo Z; Pan X; Wang G; Zhang D; Li Y; Tan B; Ouyang L; Yu X
    Respir Res; 2006 Mar; 7(1):43. PubMed ID: 16553963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-CD3 epsilon F(ab')2 fragments inhibit T cell expansion in vivo during graft-versus-host disease or the primary immune response to nominal antigen.
    Blazar BR; Jenkins MK; Taylor PA; White J; Panoskaltsis-Mortari A; Korngold R; Vallera DA
    J Immunol; 1997 Dec; 159(12):5821-33. PubMed ID: 9550378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prolonged survival of renal allografts in outbred rabbits treated with donor specific F(ab')2 alloantibody.
    Sutherland DE; Howard RJ; Dombrovskis S; Najarian JS
    Ann Surg; 1974 Dec; 180(6):857-63. PubMed ID: 4611361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protection from lethal coronavirus infection by immunoglobulin fragments.
    Lamarre A; Talbot PJ
    J Immunol; 1995 Apr; 154(8):3975-84. PubMed ID: 7706736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The protective effect of F(ab') 2 and succinylated IgG in the early treatment of hyperacute rejection in the primate.
    Habal MB; Carpenter CB; Kobayashi K; Bush GJ; Misra M; Birtch AG
    Transplant Proc; 1973 Mar; 5(1):601-6. PubMed ID: 4633093
    [No Abstract]   [Full Text] [Related]  

  • 11. Control of humoral rejection of renal allografts in presensitized monkeys by monospecific F(ab')2 fragments.
    Kahan MG; Martins AC; Macpherson SG; Wren SF; Busch GJ; Wilson RE
    Surg Forum; 1975; 26():311-3. PubMed ID: 814638
    [No Abstract]   [Full Text] [Related]  

  • 12. Anticore endotoxin F(ab')2 equine immunoglobulin fragments protect against lethal effects of gram-negative bacterial sepsis.
    Dunn DL; Mach PA; Condie RM; Cerra FB
    Surgery; 1984 Aug; 96(2):440-6. PubMed ID: 6379963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunoglobulin production by human peripheral lymphocytes induced by anti-C3 receptor antibodies.
    Daha MR; Bloem AC; Ballieux RE
    J Immunol; 1984 Mar; 132(3):1197-1201. PubMed ID: 6229578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor therapy with bispecific antibody: the targeting and triggering steps can be separated employing a CD2-based strategy.
    Wild MK; Strittmatter W; Matzku S; Schraven B; Meuer SC
    J Immunol; 1999 Aug; 163(4):2064-72. PubMed ID: 10438945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Inhibition of thrombocyte aggregation by F(ab')2-fragments of monoclonal antibodies FraMon (CRC64) to glycoproteins IIb-IIIa].
    Mazurov AV; Pevzner DV; Khaspekova SG; Dudnik OA; Byzova TV; Vlasik TN; Bakharev VN; Pistsov MIu; Staroverov II; Ruda MIa
    Ter Arkh; 2001; 73(9):66-73. PubMed ID: 11642086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of human F(ab') 2 fragments as blocking agents in the mixed lymphocyte reaction.
    Hornung MO; Layne E; McDonald JC
    J Immunol; 1971 Oct; 107(4):979-84. PubMed ID: 4999263
    [No Abstract]   [Full Text] [Related]  

  • 17. Hyperimmune F(ab') 2 antibody: role in canine hyperacute renal allograft rejection.
    Habal MB; Kobayashi K; Busch GJ; Birtch AG
    J Surg Res; 1972 Nov; 13(5):228-31. PubMed ID: 4117988
    [No Abstract]   [Full Text] [Related]  

  • 18. Nonmitogenic anti-CD3F(ab')2 fragments inhibit lethal murine graft-versus-host disease induced across the major histocompatibility barrier.
    Blazar BR; Taylor PA; Snover DC; Bluestone JA; Vallera DA
    J Immunol; 1993 Jan; 150(1):265-77. PubMed ID: 8417127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human F(ab')2-containing immune complexes together with anti-hinge natural antibodies stimulate complement amplification in vitro and in vivo.
    Fumia S; Goede JS; Fischler M; Luginbühl A; Frick S; Fodor P; Lutz HU
    Mol Immunol; 2008 May; 45(10):2951-61. PubMed ID: 18339427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Engineering Fab' fragments for efficient F(ab)2 formation in Escherichia coli and for improved in vivo stability.
    Rodrigues ML; Snedecor B; Chen C; Wong WL; Garg S; Blank GS; Maneval D; Carter P
    J Immunol; 1993 Dec; 151(12):6954-61. PubMed ID: 7903100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.